MEA Foot and Ankle Allograft Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS 1 INTRODUCTION 31 1.1 OBJECTIVES OF THE STUDY 31 1.2 MARKET DEFINITION 31 1.3 OVERVIEW OF MIDDLE EAST & AFRICA FOOT AND ANKLE ALLOGRAFTS MARKET 31 1.4 LIMITATIONS 33 1.5 MARKETS COVERED 33 2 MARKET SEGMENTATION 36 2.1 MARKETS COVERED 36 2.2 GEOGRAPHICAL SCOPE 37 2.3 YEARS CONSIDERED FOR THE STUDY 38 2.4 CURRENCY AND PRICING 38 2.5 DBMR TRIPOD DATA VALIDATION MODEL 39 2.6 MULTIVARIATE MODELLING 42 2.7 END USER LIFELINE CURVE 42 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 43 2.9 DBMR MARKET POSITION GRID 44 2.10 MARKET APPLICATION COVERAGE GRID 45 2.11 VENDOR SHARE ANALYSIS 46 2.12 SECONDARY SOURCES 47 2.13 ASSUMPTIONS 47 3 EXECUTIVE SUMMARY 48 4 PREMIUM INSIGHTS 50 4.1 PORTERS FIVE FORCES 51 5 INDUSTRIAL INSIGHTS: 52 5.1 CONCLUSION: 52 6 MIDDLE EAST & AFRICA FOOT AND ANKLE ALLOGRAFTS MARKET: REGULATIONS 53 6.1 U.S. 54 6.2 CANADA 55 6.3 EUROPE 55 7 MARKET OVERVIEW 57 7.1 DRIVERS 59 7.1.1 GROWING GERIATRIC POPULATION 59 7.1.2 INCREASE IN PREVALENCE OF MUSCULOSKELETAL DISORDER 59 7.1.3 INCREASE IN HEALTHCARE EXPENDITURE 60 7.1.4 INCREASE IN STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS 61 7.2 RESTRAINTS 62 7.2.1 STRINGENT REGULATORY 62 7.2.2 COMPLICATION AND RISK OF ALLOGRAFTS 62 7.3 OPPORTUNITIES 63 7.3.1 INCREASE IN NUMBER OF SPORTS INJURIES 63 7.3.2 RISE IN AWARENESS INITIATIVES ABOUT THE ALLOGRAFT PROCEDURE: 64 7.3.3 INCREASING RISK OF OSTEOPOROSIS AND OSTEOARTHRITIS: 65 7.4 CHALLENGES 66 7.4.1 COVID-19 IMPACT ON MIDDLE EAST & AFRICA FOOT AND ANKLE ALLOGRAFTS MARKET 66 7.4.2 ALLOGRAFT IS OFTEN CONSIDERED TOO EXPENSIVE IN LOW-INCOME TO MIDDLE-INCOME COUNTRIES: 67 7.4.3 HIGHER ADOPTION OF ALTERNATIVE THERAPIES FOR THE TREATMENT OF FOOT AND ANKLE DISORDERS: 68 8 MIDDLE EAST & AFRICA FOOT AND ANKLE ALLOGRAFTS MARKET, BY PRODUCT TYPE 69 8.1 OVERVIEW 70 8.2 ALLOGRAFT WEDGES 73 8.3 ALLOGRAFT TENDONS 73 8.4 ALLOGRAFT ACELLULAR DERMAL MATRIX 74 8.5 CARTILAGE ALLOGRAFT MATRIX 75 8.6 SKIN ALLOGRAFTS 76 8.7 AMNIOTIC MEMBRANES 77 9 MIDDLE EAST & AFRICA FOOT AND ANKLE ALLOGRAFTS MARKET, BY SURGERY TYPE 78 9.1 OVERVIEW 79 9.2 ORTHOPEDIC RECONSTRUCTION 82 9.2.1 NON-UNIONS FRACTURES 83 9.2.2 ARTHRODESIS PROCEDURES 83 9.2.3 OSTEOTOMY PROCEDURES 83 9.3 CARTILAGE RESTORATION 83 9.3.1 TALAR DOME REPAIR 84 9.3.2 TIBIAL PLAFOND REPAIR 84 9.3.3 METATARSAL REPAIR 84 9.3.4 TALONAVICULAR JOINT REPAIR 84 9.3.5 SUBTALAR JOINT REPAIR 84 9.4 SOFT TISSUE TENDON & LIGAMENT REPAIR 84 9.4.1 TENDON AUGMENTATION 85 9.4.2 LIGAMENT REPAIR 85 9.4.3 FAT PAD REPLACEMENT 85 9.4.4 PLANTAR PLATE REPAIR 86 9.5 WOUND CARE 86 9.5.1 ANKLE ULCER TREATMENT 87 9.5.2 NEUROPATHIC FOOT ULCER TREATMENT 87 10 MIDDLE EAST & AFRICA FOOT AND ANKLE ALLOGRAFTS MARKET, BY PROCEDURE 88 10.1 OVERVIEW 89 10.2 MIDFOOT PROCEDURES 92 10.2.1 CUBOID FRACTURE 93 10.2.2 FIRST TARSOMETATARSAL JOINT ARTHRODESIS 93 10.2.3 MEDIAL COLUMN ARTHRODESIS 93 10.2.4 LISFRANC 93 10.2.5 MEDIAL CUNEIFORM DORSAL OPENING WEDGE (COTTON) OSTEOTOMY 93 10.2.6 NAVICULAR CUNEIFORM ARTHRODESIS 93 10.2.7 NAVICULAR FRACTURE 93 10.2.8 OTHER MIDFOOT PROCEDURES 93 10.3 HIND-FOOT PROCEDURES 93 10.3.1 CALCANEAL FRACTURE 94 10.3.2 LATERAL COLUMN LENGTHENING 94 10.3.3 TALONAVICULAR JOINT ARTHRODESIS 95 10.3.4 TRIPLE ARTHRODESIS 95 10.3.5 OTHER HINDFOOT PROCEDURES 95 11 MIDDLE EAST & AFRICA FOOT AND ANKLE ALLOGRAFTS MARKET, BY END USER 96 11.1 OVERVIEW 97 11.2 HOSPITALS 100 11.3 ORTHOPEDIC CLINICS 100 11.4 AMBULATORY SURGICAL CENTERS 101 11.5 ACADEMIC AND RESEARCH INSTITUTES 102 11.6 OTHER END USERS 103 12 MIDDLE EAST & AFRICA FOOT AND ANKLE ALLOGRAFT MARKET, BY REGION 104 12.1 MIDDLE EAST AND AFRICA 105 12.1.1 SOUTH AFRICA 113 12.1.2 SAUDI ARABIA 116 12.1.3 U.A.E. 119 12.1.4 ISRAEL 122 12.1.5 EGYPT 125 12.1.6 REST OF MIDDLE EAST AND AFRICA 128 13 MIDDLE EAST & AFRICA FOOT AND ANKLE ALLOGRAFTS MARKET: COMPANY LANDSCAPE 129 13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 129 14 SWOT ANALYSIS 130 15 COMPANY PROFILE 131 15.1 LIFENET HEALTH 131 15.1.1 COMPANY SNAPSHOT 131 15.1.2 COMPANY SHARE ANALYSIS 131 15.1.3 PRODUCT PORTFOLIO 132 15.1.4 RECENT DEVELOPMENTS 133 15.1.4.1 CONFERENCE 133 15.1.4.2 PRODUCT LAUNCH 134 15.2 ZIMMER BIOMET 135 15.2.1 COMPANY SNAPSHOT 135 15.2.2 REVENUE ANALYSIS 135 15.2.3 COMPANY SHARE ANALYSIS 136 15.2.4 PRODUCT PORTFOLIO 136 15.2.5 RECENT DEVELOPMENT 136 15.2.5.1 PARTNERSHIP 136 15.3 JOHNSON & JOHNSON SERVICES, INC. 137 15.3.1 COMPANY SNAPSHOT 137 15.3.2 REVENUE ANALYSIS 137 15.3.3 COMPANY SHARE ANALYSIS 138 15.3.4 PRODUCT PORTFOLIO 138 15.3.5 RECENT DEVELOPMENTS 138 15.3.5.1 EVENT 138 15.3.5.2 PRODUCT LAUNCH 138 15.4 INTEGRA LIFESCIENCES 139 15.4.1 COMPANY SNAPSHOT 139 15.4.2 REVENUE ANALYSIS 139 15.4.3 COMPANY SHARE ANALYSIS 140 15.4.4 PRODUCT PORTFOLIO 140 15.4.5 RECENT DEVELOPMENTS 140 15.4.5.1 POSITIVE CLINICAL OUTCOME 140 15.4.5.2 AGREEMENT 140 15.4.5.3 ACQUISITION 141 15.5 CONMED CORPORATION (2022) 142 15.5.1 COMPANY SNAPSHOT 142 15.5.2 REVENUE ANALYSIS 142 15.5.3 COMPANY SHARE ANALYSIS 143 15.5.4 PRODUCT PORTFOLIO 143 15.5.5 RECENT DEVELOPMENT 144 15.5.5.1 ACQUISITION 144 15.6 ALLOSOURCE 145 15.6.1 COMPANY SNAPSHOT 145 15.6.2 PRODUCT PORTFOLIO 145 15.6.3 RECENT DEVELOPMENT 146 15.6.3.1 PRODUCT LAUNCH 146 15.7 ALON SOURCE GROUP 147 15.7.1 COMPANY SNAPSHOT 147 15.7.2 PRODUCT PORTFOLIO 147 15.7.3 RECENT DEVELOPMENT 147 15.8 AMNIOX MEDICAL INC. 148 15.8.1 COMPANY SNAPSHOT 148 15.8.2 PRODUCT PORTFOLIO 148 15.8.3 RECENT DEVELOPMENT 148 15.8.3.1 PARTNERSHIP 148 15.9 ARTHREX 149 15.9.1 COMPANY SNAPSHOT 149 15.9.2 PRODUCT PORTFOLIO 149 15.9.3 RECENT DEVELOPMENT 149 15.9.3.1 PRODUCT LAUNCH 149 15.10 BIOVENTUS 150 15.10.1 COMPANY SNAPSHOT 150 15.10.2 REVENUE ANALYSIS 150 15.10.3 PRODUCT PORTFOLIO 151 15.10.4 RECENT DEVELOPMENT 151 15.10.4.1 CO-DEVELOPMENT 151 15.11 BONE BANK ALLOGRAFTS 152 15.11.1 COMPANY SNAPSHOT 152 15.11.2 PRODUCT PORTFOLIO 152 15.11.3 RECENT DEVELOPMENTS 152 15.11.3.1 PARTNERSHIP 152 15.12 GLOBUS MEDICAL 153 15.12.1 COMPANY SNAPSHOT 153 15.12.2 REVENUE ANALYSIS 153 15.12.3 PRODUCT PORTFOLIO 154 15.12.4 RECENT DEVELOPMENTS 154 15.12.4.1 M&A 154 15.13 INSTITUT STRAUMANN 155 15.13.1 COMPANY SNAPSHOT 155 15.13.2 REVENUE ANALYSIS 155 15.13.3 PRODUCT PORTFOLIO 156 15.13.4 RECENT DEVELOPMENT 156 15.14 JRF ORTHO 157 15.14.1 COMPANY SNAPSHOT 157 15.14.2 PRODUCT PORTFOLIO 157 15.14.3 RECENT DEVELOPMENT 158 15.14.3.1 PARTNERSHIP 158 15.15 NVISION BIOMEDICAL TECHNOLOGIES. 159 15.15.1 COMPANY SNAPSHOT 159 15.15.2 PRODUCT PORTFOLIO 159 15.15.3 RECENT DEVELOPMENT 159 15.15.3.1 ACQUISITION 159 15.16 PARAGON28, INC. 160 15.16.1 COMPANY SNAPSHOT 160 15.16.2 REVENUE ANALYSIS 160 15.16.3 PRODUCT PORTFOLIO 161 15.16.4 RECENT DEVELOPMENT 161 15.16.4.1 ACQUISITION 161 15.17 ORGANOGENESIS INC 162 15.17.1 COMPANY SNAPSHOT 162 15.17.2 REVENUE ANALYSIS 162 15.17.3 PRODUCT PORTFOLIO 163 15.17.4 RECENT DEVELOPMENTS 163 15.17.4.1 CONFERENCE 163 15.17.4.2 ACQUISITION 163 15.18 SMITH + NEPHEW 164 15.18.1 COMPANY SNAPSHOT 164 15.18.2 REVENUE ANALYSIS 164 15.18.3 PRODUCT PORTFOLIO 165 15.18.4 RECENT DEVELOPMENTS 165 15.18.4.1 EVENT 165 15.18.4.2 ACQUISITION 165 15.19 STRYKER 166 15.19.1 COMPANY SNAPSHOT 166 15.19.2 REVENUE ANALYSIS 166 15.19.3 PRODUCT PORTFOLIO 167 15.19.4 RECENT DEVELOPMENT 167 16 QUESTIONNAIRE 168 17 RELATED REPORTS 171